サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1790175

米国の臨床検査サービスの市場規模、シェア、動向分析レポート：検査タイプ別、サービスプロバイダー別、用途別、セグメント予測、2025～2033年

U.S. Clinical Laboratory Services Market Size, Share & Trends Analysis Report By Test Type, By Service Provider, By Application, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
米国の臨床検査サービスの市場規模、シェア、動向分析レポート：検査タイプ別、サービスプロバイダー別、用途別、セグメント予測、2025～2033年
出版日: 2025年07月14日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向：

米国の臨床検査サービスの市場規模は2024年に94億2,000万米ドルと推計され、2025～2033年にかけてCAGR 5.07%を記録すると予測されています。

この市場を牽引しているのは、主に慢性疾患の負担が増加していることであり、その結果、医療現場全体でルーチン検査や専門的な診断検査の需要が高まっています。早期診断と予防的スクリーニングが重視されるようになったことで、特に糖尿病、心血管障害、がんなどの疾患に対する臨床検査サービスの利用がさらに加速しています。

さらに、サンプル検査量の増加により、データ管理とサンプル調製が顕著に改善され、より効率的な検査ワークフローと幅広い検査利用が可能になりました。このような機能強化は、ラボが納期を短縮し、診断精度を向上させ、さまざまなヘルスケア環境における需要の高まりに対応するのに役立っています。自動化システムとデジタル化された報告ツールの統合もまた、業務能力を強化し、より迅速な結果提供と臨床医と検査専門家間のより良い連携を可能にしています。

同市場はまた、同分野の大きな可能性を利用しようとする新規参入者の関心の高まりも目の当たりにしています。例えば、2023年2月、オランダのバイオテクノロジー企業Detact Diagnosticsは、2年間のレンタル契約に基づき、キーン州立大学に新しいラボを設立しました。同様に、2021年5月、Neuberg Diagnosticsは、次世代シークエンシング（NGS）と分子診断（精密医療と病気の早期発見にとって重要な分野）に特化した米国のラボを立ち上げました。これらの投資は、専門的検査の将来の展望の拡大と、将来の臨床検査サービスの形成における技術革新の役割の増大を反映しています。

さらに、進化する規制環境と価値ベースケアへの注目は、米国における臨床検査サービスの開発にさらなる影響を与えています。検査施設は、コンプライアンスを維持し、信頼性を高めるために、CLIAやCAPなどの組織によって設定された品質基準への適合をますます進めています。同時に、費用対効果と臨床的有用性を重視する支払者は、検査施設がより的を絞った検査戦略を採用することを奨励しています。このシフトは、臨床的な意思決定をサポートし、患者の転帰の改善とヘルスケア支出の最適化に貢献する、エビデンスに裏打ちされた診断の必要性を強化しています。

COVID-19パンデミック以前には、20万以上のCLIA認定検査施設で年間130億件以上の臨床検査が実施されており、ヘルスケアシステムにおける診断学の重要な役割が浮き彫りになっています。National Association of Chronic Disease Directorsによれば、2022年時点で米国人口の60％近くが少なくとも1つの慢性疾患を抱えて生活しており、このインフラは慢性疾患の管理において重要な役割を果たしています。高齢化と予防医療へのシフトに伴い、ルーチン検査や専門的検査に対する臨床需要は増加の一途をたどっています。

パンデミックは診断の重要な役割をさらに浮き彫りにし、米国では2023年3月までに11億7,000万件以上のCOVID-19検査が実施されました。このような検査能力の急増は、公衆衛生への備えを強化し、ラボインフラへの投資を加速させました。2023年2月にキーン州立大学にラボを設立したDetact Diagnosticsや、2021年5月に次世代シーケンシングと分子診断の米国ラボを立ち上げたNeuberg Diagnosticsなど、新規参入企業は市場の潜在力を積極的に活用しています。さらに、ProPhase Labsは2024年11月にDNA Complete, Inc.を発表しました。DNA Complete, Inc.は、個別化診断への市場の指向の高まりを反映した、消費者直販のDNA検査プラットフォームです。がん罹患率の上昇は、2024年には新規罹患者数が200万人を超えると予測されており、特に腫瘍学に特化した検査など、高度な検査サービスに対する継続的な需要をさらに強めています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の臨床検査サービス市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/付随市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 米国の臨床検査サービス市場の分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国の臨床検査サービス市場：検査タイプ別、推定・動向分析

  • 市場シェア：検査タイプ別、2024年および2033年
  • セグメントダッシュボード
  • 検査タイプ別展望
  • 市場規模、予測・動向分析、2021～2033年
    • 遺伝子検査
    • 臨床化学
    • 医療微生物検査
    • 血液検査
    • 免疫学的検査
    • 細胞診検査
    • 薬物乱用検査
    • その他

第5章 米国の臨床検査サービス市場：サービスプロバイダー別、推定・動向分析

  • 市場シェア：サービスプロバイダー別、2024年および2033年
  • セグメントダッシュボード
  • サービスプロバイダー別展望
  • 市場規模、予測・動向分析、2021～2033年
    • 病院併設ラボ
    • 独立型ラボ
    • クリニック併設ラボ

第6章 米国の臨床検査サービス市場：用途別、推定・動向分析

  • 市場シェア：用途別、2024年および2033年
  • セグメントダッシュボード
  • 用途別展望
  • 市場規模、予測・動向分析、2021～2033年
    • バイオ分析・ラボ化学サービス
    • 毒性試験サービス
    • 細胞・遺伝子治療関連サービス
    • 前臨床・臨床試験関連サービス
    • 創薬・開発関連サービス
    • その他

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店およびチャネルパートナーのリスト
    • Key customers
    • Key company market share analysis, 2024
    • LABORATORY CORPORATION OF AMERICA HOLDINGS（LABCORP）
    • Eurofins Scientific SE
    • QIAGEN NV
    • Quest Diagnostics Incorporated
    • OPKO HEALTH, INC.
    • Charles River Laboratories International, Inc.
    • ARUP LABORATORIES
    • Sonic Healthcare
    • Neogenomics Laboratories
    • Fresenius Medical Care
    • Siemens Medical Solutions USA, Inc.
    • SYNLAB International GmbH
    • Mayo Clinic Laboratories
    • Unilabs
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. Clinical laboratory services market, by test type, 2021 - 2033 (USD Million)
  • Table 3 U.S. Clinical laboratory services market, by service provider, 2021 - 2033 (USD Million)
  • Table 4 U.S. Clinical laboratory services market, by application, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. clinical laboratory services market: market outlook
  • Fig. 10 U.S. clinical laboratory services competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Clinical laboratory services market driver impact
  • Fig. 16 U.S. Clinical laboratory services market restraint impact
  • Fig. 17 U.S. Clinical laboratory services market strategic initiatives analysis
  • Fig. 18 U.S. Clinical laboratory services market: Test Type movement analysis
  • Fig. 19 U.S. Clinical laboratory services market: Test Type outlook and key takeaways
  • Fig. 20 Genetic Testing market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Clinical chemistry market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 22 Routine chemistry testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 23 Therapeutic drug monitoring testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 24 Endocrinology chemistry testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 25 Specialized chemistry testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 26 Other clinical chemistry testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 27 Medical microbiology testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 28 Infectious disease testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 29 Transplant diagnostic testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 30 Other microbiology testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 31 Hematology testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 32 Immunology testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 33 Cytology testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 34 Drug of abuse testing market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 35 Other esoteric tests market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 36 U.S. Clinical laboratory services market: Service Provider movement Analysis
  • Fig. 37 U.S. Clinical laboratory services market: Service Provider outlook and key takeaways
  • Fig. 38 Hospital-based laboratories market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 39 Stand-alone laboratories market estimates and forecasts 2021 - 2033 (USD Million)
  • Fig. 40 Clinic-based laboratories market estimates and forecasts 2021 - 2033 (USD Million)
  • Fig. 41 U.S. Clinical laboratory services market: application movement analysis
  • Fig. 42 U.S. Clinical laboratory services market: application outlook and key takeaways
  • Fig. 43 Bioanalytical & lab chemistry services market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 44 Toxicology testing services market estimates and forecasts 2021 - 2033 (USD Million)
  • Fig. 45 Cell & gene therapy related services market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 46 Preclinical & clinical trial related services market estimates and forecasts 2021 - 2033 (USD Million)
  • Fig. 47 Drug discovery & development related services market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 48 Other U.S. Clinical laboratory services market estimates and forecasts 2021 - 2033 (USD Million)
  • Fig. 49 U.S. Clinical laboratory services market share and leading players
  • Fig. 50 U.S. market share and leading players
  • Fig. 51 U.S. SWOT
  • Fig. 52 U.S. market estimates and forecast 2021 - 2033 (USD Million)
  • Fig. 53 Market share of key market players - U.S. Clinical laboratory services market
目次
Product Code: GVR-4-68040-670-3

Market Size & Trends:

The U.S. clinical laboratory services market size was estimated at USD 9.42 billion in 2024 and is projected to register a CAGR of 5.07% from 2025 to 2033. The market is primarily driven by the increasing burden of chronic diseases, which has intensified the demand for routine and specialized diagnostic testing across care settings. Rising emphasis on early diagnosis and preventive screening has further accelerated the use of clinical laboratory services, particularly for conditions such as diabetes, cardiovascular disorders, and cancer.

In addition, the growing volume of sample testing has led to notable improvements in data management and sample preparation, supporting more efficient laboratory workflows and broader test availability. These enhancements are helping laboratories reduce turnaround times, improve diagnostic accuracy, and handle rising demand across various healthcare settings. Integration of automated systems and digitized reporting tools is also strengthening operational capacity, enabling faster delivery of results and better coordination between clinicians and lab professionals.

The market is also witnessing growing interest from new entrants aiming to capitalize on the sector's strong potential. Driven by the sector's lucrative prospects, new entrants are actively investing in the U.S. For instance, in February 2023, Dutch biotech firm Detact Diagnostics established a new laboratory at Keene State College under a two-year rental agreement. Similarly, in May 2021, Neuberg Diagnostics launched a U.S. lab focused on next-generation sequencing (NGS) and molecular diagnostics-key areas for precision medicine and early disease detection. These investments reflect the expanding scope of specialized testing and the increasing role of innovation in shaping future clinical laboratory services.

Moreover, the evolving regulatory environment and focus on value-based care are further influencing the development of clinical laboratory services in the U.S. Laboratories are increasingly aligning with quality standards set by organizations such as CLIA and CAP to maintain compliance and enhance credibility. At the same time, payers' emphasis on cost-effectiveness and clinical utility encourages labs to adopt more targeted testing strategies. This shift reinforces the need for evidence-backed diagnostics that support clinical decision-making and contribute to improved patient outcomes and optimized healthcare spending.

Prior to the COVID-19 pandemic, over 13 billion clinical tests were conducted annually across more than 200,000 CLIA-certified laboratories, highlighting the essential role of diagnostics in the healthcare system. This infrastructure plays a key role in managing chronic conditions, with nearly 60% of the U.S. population living with at least one chronic disease as of 2022, according to the National Association of Chronic Disease Directors. The clinical demand for routine and specialized testing continues to rise with the country's aging population and the shift toward preventive care.

The pandemic further underscored the critical role of diagnostics, with over 1.17 billion COVID-19 tests performed in the U.S. by March 2023. This surge in testing capacity has strengthened public health preparedness and accelerated investment in lab infrastructure. New entrants are actively tapping into the market's potential, such as Detact Diagnostics, which established a laboratory at Keene State College in February 2023, and Neuberg Diagnostics, which launched a U.S. lab for next-generation sequencing and molecular diagnostics in May 2021. In addition, ProPhase Labs introduced DNA Complete, Inc. in November 2024, a direct-to-consumer DNA testing platform reflecting the market's growing orientation toward personalized diagnostics. Rising cancer incidence-projected to exceed 2 million new cases in 2024-further reinforces the ongoing demand for advanced laboratory services, particularly in oncology-focused testing.

U.S. Clinical Laboratory Services Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. clinical laboratory services market report based on test type,application, and service provider:

  • Test Type Outlook (Revenue in USD Million, 2021 - 2033)
  • Genetic Testing
  • Clinical Chemistry
    • Routine Chemistry Testing
    • Therapeutic Drug Monitoring Testing
    • Endocrinology Chemistry Testing
    • Specialized Chemistry Testing
    • Other Clinical Chemistry Testing
  • Medical Microbiology Testing
    • Infectious Disease Testing
    • Transplant Diagnostic Testing
    • Other Microbiology Testing
  • Hematology Testing
  • Immunology Testing
  • Cytology Testing
  • Drug of Abuse Testing
  • Other Esoteric Tests
  • Service Provider Outlook (Revenue in USD Million, 2021 - 2033)
  • Hospital-Based Laboratories
  • Stand-Alone Laboratories
  • Clinic-Based Laboratories
  • Application Outlook (Revenue in USD Million, 2021 - 2033)
  • Bioanalytical & Lab Chemistry Services
  • Toxicology Testing Services
  • Cell & Gene Therapy Related Services
  • Preclinical & Clinical Trial Related Services
  • Drug Discovery & Development Related Services
  • Other Clinical Laboratory Services

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Test Type
    • 1.2.2. Service Provider
    • 1.2.3. Application
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in U.S.
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test Type outlook
    • 2.2.2. Service Provider outlook
    • 2.2.3. Application outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Clinical Laboratory Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements in the field of clinical testing
      • 3.2.1.2. Growing prevalence of target diseases coupled with rising demand for early disease diagnostic tests
      • 3.2.1.3. Introduction of novel solutions
      • 3.2.1.4. Outbreak of COIVD-19 pandemic
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Presence of stringent regulatory framework
  • 3.3. U.S. Clinical laboratory services market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Clinical laboratory services market: Test Type Estimates & Trend Analysis

  • 4.1. Test Type Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. U.S. Clinical laboratory services market by Test Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Genetic Testing
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Clinical Chemistry
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.2. Routine Chemistry Testing Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.3. Therapeutic Drug Monitoring Testing Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.4. Endocrinology Chemistry Testing Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.5. Specialized Chemistry Testing Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.6. Other Clinical Chemistry Testing Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Medical Microbiology Testing
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.3.2. Infectious Disease Testing Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.3.3. Transplant Diagnostic Testing Market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.3.4. Other Microbiology Testing Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Hematology Testing
      • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Immunology Testing
      • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6. Cytology Testing
      • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7. Drug of Abuse Testing
      • 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8 Other Esoteric Tests
      • 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Clinical Laboratory Services Market: Service Provider Estimates & Trend Analysis

  • 5.1. Service Provider Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Clinical laboratory services market by Service Provider Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Hospital-Based Laboratories
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Stand-Alone Laboratories
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. Clinic-Based Laboratories
      • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Clinical Laboratory Services Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. U.S. Clinical laboratory services market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Bioanalytical & Lab Chemistry Services
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Toxicology Testing Services
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Cell & Gene Therapy Related Services
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. Preclinical & Clinical Trial Related Services
      • 6.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.5. Drug Discovery & Development Related Services
      • 6.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Eurofins Scientific SE
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Product benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. QIAGEN NV
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Quest Diagnostics Incorporated
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. OPKO HEALTH, INC.
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Charles River Laboratories International, Inc.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. ARUP LABORATORIES
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Sonic Healthcare
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Neogenomics Laboratories
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. Fresenius Medical Care
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Siemens Medical Solutions USA, Inc.
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives
    • 7.3.15. SYNLAB International GmbH
      • 7.3.15.1. Company overview
      • 7.3.15.2. Financial performance
      • 7.3.15.3. Product benchmarking
      • 7.3.15.4. Strategic initiatives
    • 7.3.16. Mayo Clinic Laboratories
      • 7.3.16.1. Company overview
      • 7.3.16.2. Financial performance
      • 7.3.16.3. Product benchmarking
      • 7.3.16.4. Strategic initiatives
    • 7.3.17. Unilabs
      • 7.3.17.1. Company overview
      • 7.3.17.2. Financial performance
      • 7.3.17.3. Product benchmarking
      • 7.3.17.4. Strategic initiatives